Drug intelligence / Profile preview

azithromycin + rifabutin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination antibiotic therapy consisting of azithromycin (a macrolide antibiotic) and rifabutin (a rifamycin derivative). This combination is primarily used for the prevention and treatment of Mycobacterium avium complex (MAC) infections in immunocompromised patients, particularly those with HIV infection. The combination has shown greater efficacy than rifabutin alone in preventing MAC infections, though it is associated with significant tolerability issues including gastrointestinal symptoms and neutropenia.

Targets

rpoB (DNA-directed RNA polymerase subunit beta)23S rRNA (23S ribosomal RNA)

Beyond the preview

Go deeper on azithromycin + rifabutin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azithromycin + rifabutin.

Explore the full profile